Mary Bleszcz-Marmorato
Family · Little River, SCNPI 1811201411
Payments from drug & device makers
Across 39 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$110
- Next Science LLC$96
- Dentsply IH Inc.$73
- Smith+Nephew$65
- KCI USA, Inc.$63
- Rochester Medical Corporation$56
- plus $288 from 10 others
What the payments were for
- Food & beverage$751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 4 | $110 |
| Next Science LLC | 6 | $96 |
| Dentsply IH Inc. | 1 | $73 |
| Smith+Nephew | 3 | $65 |
| KCI USA, Inc. | 3 | $63 |
| Rochester Medical Corporation | 3 | $56 |
| Urovant Sciences Inc | 3 | $47 |
| Myovant Sciences Inc. | 3 | $44 |
| Bioventus LLC | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Antares Pharma, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $15 |
| OVIK Health, LLC | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
How this compares
$751 in reported general payments places this provider in the 60th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $9,093 |
| Tamsulosin Hcl | 143 | $1,985 |
| Finasteride | 61 | $1,056 |
| Estradiol | 13 | $703 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $193 |
| Cephalexin | 24 | $143 |
| Doxycycline Hyclate | 19 | $92 |
Paid to pharmacies, not to this prescriber.
Other family in Little River
- Sara LaraLittle River$11K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.